Onesource Specialty Pharma and Shaily Engineering Plastics gained as investors bet on India’s role in the global GLP-1 semaglutide supply chain, despite Onesource’s weak Q3 results
Onesource Specialty Pharma and Shaily Engineering Plastics gained as investors bet on India’s role in the global GLP-1 semaglutide supply chain, despite Onesource’s weak Q3 results